Review



dna optimised for e. coli expression  (Entelechon GmbH)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Entelechon GmbH dna optimised for e. coli expression
    Dna Optimised For E. Coli Expression, supplied by Entelechon GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optimisations/dna+optimised+for+e++coli+expression/us10081803-344-0-10
    Average 90 stars, based on 1 article reviews
    dna optimised for e. coli expression - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser-Ile-Glu-Gly-Arg-Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 53) incorporating an IEGR peptide (SEQ ID NO: 33), a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG (SEQ ID NO: 51)).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG) (SEQ ID NO: 51).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 50) incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 31 amino acid beta-endorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 40 amino acid GHRH peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 40 amino acid GHRH peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating a DDDDK (SEQ ID NO: 32) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 17 amino acid dynorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Purification:

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser-Ile-Glu-Gly-Arg-Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 53) incorporating an IEGR peptide (SEQ ID NO: 33), a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG (SEQ ID NO: 51)).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG) (SEQ ID NO: 51).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 50) incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 31 amino acid beta-endorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 40 amino acid GHRH peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 40 amino acid GHRH peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating a DDDDK (SEQ ID NO: 32) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 17 amino acid dynorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Sequencing:

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser-Ile-Glu-Gly-Arg-Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 53) incorporating an IEGR peptide (SEQ ID NO: 33), a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG (SEQ ID NO: 51)).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG) (SEQ ID NO: 51).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 50) incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 31 amino acid beta-endorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 40 amino acid GHRH peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 40 amino acid GHRH peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating a DDDDK (SEQ ID NO: 32) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 17 amino acid dynorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Modification:

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser-Ile-Glu-Gly-Arg-Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 53) incorporating an IEGR peptide (SEQ ID NO: 33), a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG (SEQ ID NO: 51)).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG) (SEQ ID NO: 51).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 50) incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 31 amino acid beta-endorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 40 amino acid GHRH peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 40 amino acid GHRH peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating a DDDDK (SEQ ID NO: 32) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 17 amino acid dynorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Residue:

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser-Ile-Glu-Gly-Arg-Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 53) incorporating an IEGR peptide (SEQ ID NO: 33), a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG (SEQ ID NO: 51)).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG) (SEQ ID NO: 51).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 50) incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 31 amino acid beta-endorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 40 amino acid GHRH peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 40 amino acid GHRH peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating a DDDDK (SEQ ID NO: 32) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 17 amino acid dynorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Software:

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser-Ile-Glu-Gly-Arg-Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 53) incorporating an IEGR peptide (SEQ ID NO: 33), a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG (SEQ ID NO: 51)).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly (QHWSYCLRPG) (SEQ ID NO: 51).

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser spacer (SEQ ID NO: 50) incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 31 amino acid beta-endorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 40 amino acid GHRH peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 40 amino acid GHRH peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 amino acid asparagine spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating a DDDDK (SEQ ID NO: 32) peptide sequence at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/D, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/D modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR (SEQ ID NO: 33) peptide sequence at the C-terminus a 17 amino acid dynorphin peptide a 11 amino acid Gly-Gly-Gly-Gly-Ser-Cys-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 52) a 9 amino acid bradykinin peptide.

    Article Title: Therapeutic fusion proteins
    Article Snippet: DNA optimised for E. coli expression is obtained commercially from Entelechon (Germany) to encode a fusion protein which has the following structure, from N- to C-terminus: 10 His N-terminal purification tag (SEQ ID NO: 48), a 10 asparagine amino acid spacer (SEQ ID NO: 49), the LC of BoNT/A, an inter-domain linker with a primary sequence similar to the found in BoNT/A, modified to incorporate the tetra peptide IEGR (SEQ ID NO: 33) which is a substrate for FXa, the HN of BoNT/A modified to incorporate a C-terminal Cys, a Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 50) spacer incorporating an IEGR peptide sequence (SEQ ID NO: 33) at the C-terminus a 10 amino acid GnRH peptide modified to incorporate a Cys residue at position 6 in place of the natural Gly.



    Similar Products

    optimisation model ☆  (Bioresource Technology Inc)
    86
    Bioresource Technology Inc optimisation model ☆
    Optimisation Model ☆, supplied by Bioresource Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optimisations/model+optimisation+%E2%98%86/pm42297255-14-1-18
    Average 86 stars, based on 1 article reviews
    optimisation model ☆ - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    optimisation framework 400a  (Optimus Corp)
    86
    Optimus Corp optimisation framework 400a
    Optimisation Framework 400a, supplied by Optimus Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optimisations/400a+framework+optimisation/us12650996-222-1-9
    Average 86 stars, based on 1 article reviews
    optimisation framework 400a - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    e coli codon optimised amenc spycatcher am s sequence  (Twist Bioscience)
    86
    Twist Bioscience e coli codon optimised amenc spycatcher am s sequence
    ( a ) Schematics depicting ( left ) <t>the</t> <t>Am-S</t> genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).
    E Coli Codon Optimised Amenc Spycatcher Am S Sequence, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optimisations/codon+experiments+expression+klhdc3+mouse+mouse+optimised+re/bio_rxiv__64898__2026__06__01__729406-245-1-15
    Average 86 stars, based on 1 article reviews
    e coli codon optimised amenc spycatcher am s sequence - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    codon optimised scfv  (Eurofins)
    86
    Eurofins codon optimised scfv
    ( a ) Schematics depicting ( left ) <t>the</t> <t>Am-S</t> genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).
    Codon Optimised Scfv, supplied by Eurofins, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optimisations/codon+optimised+scfv/10__1016_slash_j__jcyt__2026__102930-147-1-14
    Average 86 stars, based on 1 article reviews
    codon optimised scfv - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    gis based optimisation  (Chennai Corporation)
    86
    Chennai Corporation gis based optimisation
    ( a ) Schematics depicting ( left ) <t>the</t> <t>Am-S</t> genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).
    Gis Based Optimisation, supplied by Chennai Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optimisations/based+gis+optimisation/10__1177_slash_0734242x261437538-18-23-26
    Average 86 stars, based on 1 article reviews
    gis based optimisation - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    codon optimised sequence  (Twist Bioscience)
    86
    Twist Bioscience codon optimised sequence
    ( a ) Schematics depicting ( left ) <t>the</t> <t>Am-S</t> genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).
    Codon Optimised Sequence, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optimisations/codon+optimized/pm42115646-294-14-17
    Average 86 stars, based on 1 article reviews
    codon optimised sequence - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    codon optimised mprf gene  (Twist Bioscience)
    86
    Twist Bioscience codon optimised mprf gene
    ( a ) Schematics depicting ( left ) <t>the</t> <t>Am-S</t> genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).
    Codon Optimised Mprf Gene, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optimisations/codon+experiments+expression+klhdc3+mouse+mouse+optimised+re/bio_rxiv__64898__2026__04__24__720753-96-1-37
    Average 86 stars, based on 1 article reviews
    codon optimised mprf gene - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    u1144 optimisation thérapeutique en neuropharmacologie opten  (Inserm Transfert)
    86
    Inserm Transfert u1144 optimisation thérapeutique en neuropharmacologie opten
    ( a ) Schematics depicting ( left ) <t>the</t> <t>Am-S</t> genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).
    U1144 Optimisation Thérapeutique En Neuropharmacologie Opten, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optimisations/1140+en+france+h%C3%A9mostase+innovation+inserm+th%C3%A9rapeutique+umrs/pm41899390-0-2-1
    Average 86 stars, based on 1 article reviews
    u1144 optimisation thérapeutique en neuropharmacologie opten - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    ( a ) Schematics depicting ( left ) the Am-S genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).

    Journal: bioRxiv

    Article Title: Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines

    doi: 10.64898/2026.06.01.729406

    Figure Lengend Snippet: ( a ) Schematics depicting ( left ) the Am-S genetic construct encoding the AmEnc subunit (grey) fused at the C-terminus to SpyCatcher (orange) via a linker comprising a His-tag (green) flanked by flexible (GGGS) n spacers (white); and ( right ) covalent coupling of SpyTagged antigens to the surface of the self-assembled Am-S scaffold, generating an antigen-displaying nanovaccine. ( b ) PAGE analysis of Am-S purified by sequential IMAC and SEC: ( left ) SDS-PAGE showing the Am-S subunit (∼44 kDa); ( right ) native PAGE verifying nanocage assembly. ( c ) DLS analysis demonstrating monodisperse Am-S nanocages with a mean hydrodynamic diameter of 36.4 ± 9.4 nm. ( d ) ( left ) Cryo-EM micrograph showing Am-S self-assembly into nanocage structures (scale bar = 100 nm) ( right ) 3D reconstruction at 2.58 Å resolution (external view) confirming high-fidelity assembly into 21.2 nm particles with T = 1 icosahedral symmetry. ( e–j ) Storage stability of Am-S. ( e ) Solubility after 1 and 4 freeze-thaw cycles; untreated material (0) was defined as 100% soluble. ( f ) DLS analysis of samples in (e). ( g ) Solubility after storage at the indicated temperatures for 6 weeks; samples stored at −80 °C were defined as 100% soluble. ( h ) DLS analysis of samples in (g). ( i ) Solubility before and after lyophilisation and storage at ambient temperature for 1 day; pre-lyophilisation material was defined as 100% soluble. ( j ) DLS analysis of samples in (i). Soluble Am-S fractions were isolated by centrifugation and quantified by SDS-PAGE densitometry (mean ± SD, n = 3).

    Article Snippet: The E. coli codon optimised AmEnc-SpyCatcher (Am-S) sequence ( Table S2 ) was synthesised by Twist Bioscience into the pET-24(+) expression vector and transformed into E. coli BL21(DE3) competent cells (New England Biolabs).

    Techniques: Construct, Purification, SDS Page, Clear Native PAGE, Cryo-EM Sample Prep, Solubility, Isolation, Centrifugation

    ( a ) Schematic of peptide antigens with an N-terminal SpyTag (orange) linked via a flexible (GS)n spacer (black) to peptide antigens derived from pTau (S-pTau; green) or Aβ (S-Aβ; purple). ( b ) Conceptual illustration of unconjugated and conjugated Am-S, including the bare nanoscaffold (Am-S), monovalent nanocage formats bearing S-pTau (Am-S-pTau) or S-Aβ (Am-S-Aβ), and a multivalent “mosaic” nanocage bearing both antigens. ( c ) PAGE assessment of SpyTag/SpyCatcher-mediated conjugation, with ( left ) SDS-PAGE showing covalent coupling of antigen(s) to the Am-S subunit, and ( right ) non-denaturing native PAGE indicating antigen (co-)display on the assembled Am-S nanocage. ( d ) DLS characterisation of hydrodynamic diameter and dispersity of the (co-)conjugated nanocages. ( e ) Negatively stained TEM images of Am-S (orange), Am-S-pTau (green), Am-S-Aβ (purple), and mosaic (blue) nanocage formats; Scale bars = 200 nm.

    Journal: bioRxiv

    Article Title: Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines

    doi: 10.64898/2026.06.01.729406

    Figure Lengend Snippet: ( a ) Schematic of peptide antigens with an N-terminal SpyTag (orange) linked via a flexible (GS)n spacer (black) to peptide antigens derived from pTau (S-pTau; green) or Aβ (S-Aβ; purple). ( b ) Conceptual illustration of unconjugated and conjugated Am-S, including the bare nanoscaffold (Am-S), monovalent nanocage formats bearing S-pTau (Am-S-pTau) or S-Aβ (Am-S-Aβ), and a multivalent “mosaic” nanocage bearing both antigens. ( c ) PAGE assessment of SpyTag/SpyCatcher-mediated conjugation, with ( left ) SDS-PAGE showing covalent coupling of antigen(s) to the Am-S subunit, and ( right ) non-denaturing native PAGE indicating antigen (co-)display on the assembled Am-S nanocage. ( d ) DLS characterisation of hydrodynamic diameter and dispersity of the (co-)conjugated nanocages. ( e ) Negatively stained TEM images of Am-S (orange), Am-S-pTau (green), Am-S-Aβ (purple), and mosaic (blue) nanocage formats; Scale bars = 200 nm.

    Article Snippet: The E. coli codon optimised AmEnc-SpyCatcher (Am-S) sequence ( Table S2 ) was synthesised by Twist Bioscience into the pET-24(+) expression vector and transformed into E. coli BL21(DE3) competent cells (New England Biolabs).

    Techniques: Derivative Assay, Conjugation Assay, SDS Page, Clear Native PAGE, Staining

    ( a ) Immunisation schedule for C57BL/6J mice ( n = 4 per group) with end-point sera collection. ( b ) ELISA measurement of anti-pTau total IgG levels in terminal sera from mice receiving Am-S-pTau and controls. ( c ) Body-weight change of mice over time-course in (b), expressed as normalised area under the curve (AUC). ( Right panel ) AddaVax™ and Alhydrogel®. ( d ) Immunisation and sera collection schedule for mice receiving Am-S-pTau formulated with ADV or ALH ( n = 4 per group). ( e ) Anti-pTau IgG titres in sera over time. Black arrows indicate immunization days. ( f ) Body-weight change over time in (e). Data are mean ± SD. ****P < 0.0001; ns, non-significant (> 0.05). Statistical analyses: one-way ANOVA with Tukey’s multiple comparisons for (b,c,f); two-way mixed-effects ANOVA with time and adjuvant as factors for (e).

    Journal: bioRxiv

    Article Title: Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines

    doi: 10.64898/2026.06.01.729406

    Figure Lengend Snippet: ( a ) Immunisation schedule for C57BL/6J mice ( n = 4 per group) with end-point sera collection. ( b ) ELISA measurement of anti-pTau total IgG levels in terminal sera from mice receiving Am-S-pTau and controls. ( c ) Body-weight change of mice over time-course in (b), expressed as normalised area under the curve (AUC). ( Right panel ) AddaVax™ and Alhydrogel®. ( d ) Immunisation and sera collection schedule for mice receiving Am-S-pTau formulated with ADV or ALH ( n = 4 per group). ( e ) Anti-pTau IgG titres in sera over time. Black arrows indicate immunization days. ( f ) Body-weight change over time in (e). Data are mean ± SD. ****P < 0.0001; ns, non-significant (> 0.05). Statistical analyses: one-way ANOVA with Tukey’s multiple comparisons for (b,c,f); two-way mixed-effects ANOVA with time and adjuvant as factors for (e).

    Article Snippet: The E. coli codon optimised AmEnc-SpyCatcher (Am-S) sequence ( Table S2 ) was synthesised by Twist Bioscience into the pET-24(+) expression vector and transformed into E. coli BL21(DE3) competent cells (New England Biolabs).

    Techniques: Enzyme-linked Immunosorbent Assay, Adjuvant

    Representative immunohistochemical staining of (Left panel) amygdala sections from tauopathy TAU58/2 mice with the corresponding region from wild-type mice controls ( n = 1); and (Right panel) hippocampal sections from amyloidogenic APP/PS1 mice with the corresponding region from wild-type controls ( n = 1). As indicated, ex vivo brain sections were incubated with sera from C57BL/6J mice immunised with single-targeting nanovaccines (Am-S-pTau or Am-S-Aβ), or dual-targeting mosaic or cocktail formulations. Positive control antibodies were included: PHF-1 that recognizes pTau (pSer396/404); or 6E10 that binds Aβ (residues 1-16/17). Pathology-bound IgG was detected using Alexa Fluor 488 (green) and Alexa Fluor 568 or 647 (orange). Cell nuclei were counterstained with DAPI (blue). Scale bars = 200 µm (TAU58/2); or 500 µm (APP/PS1) and 200 µm (zoomed-in region, APP-PS1).

    Journal: bioRxiv

    Article Title: Engineering a Novel Bacterial Encapsulin for Programmable Surface Functionalization: From Single-Target to Mosaic Nanovaccines

    doi: 10.64898/2026.06.01.729406

    Figure Lengend Snippet: Representative immunohistochemical staining of (Left panel) amygdala sections from tauopathy TAU58/2 mice with the corresponding region from wild-type mice controls ( n = 1); and (Right panel) hippocampal sections from amyloidogenic APP/PS1 mice with the corresponding region from wild-type controls ( n = 1). As indicated, ex vivo brain sections were incubated with sera from C57BL/6J mice immunised with single-targeting nanovaccines (Am-S-pTau or Am-S-Aβ), or dual-targeting mosaic or cocktail formulations. Positive control antibodies were included: PHF-1 that recognizes pTau (pSer396/404); or 6E10 that binds Aβ (residues 1-16/17). Pathology-bound IgG was detected using Alexa Fluor 488 (green) and Alexa Fluor 568 or 647 (orange). Cell nuclei were counterstained with DAPI (blue). Scale bars = 200 µm (TAU58/2); or 500 µm (APP/PS1) and 200 µm (zoomed-in region, APP-PS1).

    Article Snippet: The E. coli codon optimised AmEnc-SpyCatcher (Am-S) sequence ( Table S2 ) was synthesised by Twist Bioscience into the pET-24(+) expression vector and transformed into E. coli BL21(DE3) competent cells (New England Biolabs).

    Techniques: Immunohistochemical staining, Staining, Ex Vivo, Incubation, Positive Control